Erenumab
As of the edition of 20 October 2026, Erenumab is an antibody: marketed, first approved in 2018 (US); acts on CALCRL; US protection ends in 2030.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Antibody
- Brand name
- Aimovig
- First approved
- 17 May 2018 (US)
- Approvals on record
- 11 in 4 regions
- Holder of the most recent approval
- Amgen; 3 holders in all
- Registered trials
- 53, 6 stopped early
- Disease areas
- Nervous system; Injuries; Bones, joints and muscles; Cancer; Ear, nose and throat; Eye
US protection
US protection ends in 2030.
US protection ends in 2030, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Amgen. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Erenumab.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CALCRL | Calcitonin gene-related peptide type 1 receptor | Q16602 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 1 | 4 | 0 |
| Phase 1 | 9 | 8 | 0 | 1 |
| Phase 2 | 12 | 8 | 2 | 1 |
| Phase 3 | 9 | 6 | 1 | 2 |
| Phase 4 | 15 | 9 | 1 | 2 |
| All trials | 53 |